Table 2 Efficacy outcomes. ECF, 5-fluorouracil, cisplatin, and epirubicin; PFS, progression-free survival; OS, overall survival.

From: Exploring the efficacy of fluorouracil and platinum based chemotherapy in advanced hepatocellular carcinoma to bridge the treatment gap in resource limited settings

 

ECF (n = 48)

Best response

 

Complete response

0

Partial response

7 (14.6%)

Stable disease

22 (45.8%)

Progressive disease

19 (39.6%)

Objective response rate

7 (14.6%)

Disease control rate

29 (60.4%)

Median PFS, months [95% CI]

4.2 [1.3–7.1]

6-month PFS, % [95% CI]

38.3 [24.6–51.8]

Median OS, months [95% CI]

8.2 [2.5–13.9]

1-year OS, % [95% CI]

46.8 [32.1–60.2]

Back to article page